Business
Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting
Preclinical Data Highlight Strong Monotherapy Anti-Tumor Activity Across Multiple Acute Myeloid Leukemia Models and Combination Potential with Other Agents
About this update from Schrodinger, Inc.
[{"type":"text","content":"\nPreclinical Data Highlight Strong Monotherapy Anti-Tumor Activity Across Multiple Acute Myeloid Leukemia Models and Combination Potential with Other Agents\n\nOn Track to Submit Investigational New Drug Application for SGR-2921 to the U.S. Food and Drug Administration in the First Half of 2023\n\n NEW YORK--(BUSINESS WIRE)--\nSchrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced new preclinical data on its potent and selective CDC7 inhibitor, SGR-2921, in a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana. The data presented demonstrate that SGR-2921 exhibits strong anti-tumor activity in vivo across multiple acute myeloid leukemia (AML) models, including cell-derived xenograft models, as a monotherapy and in combination with standard of care agents. Moreover, SGR-2921 demonstrates anti-tumor activity in AML patient-derived samples resistant to standard of care agents.\n\nCDC7 is a cell cycle kinase involved in DNA replication and is an important activator of replication stress and DNA damage responses. CDC7 inhibition is considered a promising therapeutic approach for the treatment of cancers, including AML. Schrödinger is advancing SGR-2921 through investigational new drug (IND)-enabling studies with plans to submit an IND application to the U.S. Food and Drug Administration in the first half of 2023 and to initiate a Phase 1 clinical trial in patients with relapsed/refractory AML in the second half of 2023.\n\n“The strength of our preclinical data presented today underscore the power of our computational platform to overcome drug design challenges that plague the industry, in this case designing a potent CDC7 inhibitor that could potentially be combined with other DNA damage repair therapies, such as PARP and BCL-2 inhibitors,” said Karen Akinsanya, Ph.D., president of R&D, therapeutics, at Schrödinger. “We are pleased that our data show that SGR-2921-mediated CDC7 inhibition represents a promising novel therapeutic strategy for treating AML, with potential utility in patients with relapsed and refractory AML, and we look forward to advancing this potential best-in-class inhibitor into the clinic.”\n\nAdditional Details About the Study\nT...